Achillion Pharmaceuticals

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Achillion Pharmaceuticals ( ACHN) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The stock is trading up 23.4% at $10.80 in recent trading.

Today's Volume: 5 million

Average Volume: 1.4 million

Volume % Change: 401%

>>5 Biotech Stocks for 2012

Shares of ACHN are soaring today after Gilead Sciences ( GILD) reported disappointing trial results for its experimental hepatitis C drug. Shares of ACHN, along with Vertex Pharmaceutical ( VRTX) and Idenix Pharmaceutical ( IDIX), are ripping higher because they are rival hepatitis C drug developers to Gilead.

From a technical perspective, ACHN is gapping up huge today on monster volume back above its 50-day moving average of $9.34.

Traders should now watch for a sustained high-volume move and close near its daily high of $11.14 to signal that ACHN wants to trend much higher. At last check, the stock is trading at $10.80 and volume is well above its average of 1.4 million shares. If we get that strong close today, then traders should continue to look for long biased trades that take this stock back towards its next major overhead resistance levels at $12.46 to $12.95 in the near future.

If you liked this article you might like

Achillion Shares Are Plunging on Termination of Hepatitis C Pact

Achillion Pharmaceuticals Stock Falls, Baird Downgrades Over Lack of Confidence